NRAS Mutations Are Rare in Colorectal Cancer
Year: 2010
Type: article
Study design: Observational Study
Abstract: Activating mutations in members of the RAS oncogene family (KRAS, HRAS, and NRAS) have been found in a variety of human malignancies, suggesting a dominant role in carcinogenesis. In colon cancers, KRAS mutations are common and clearly contribute to malignant progression. The frequency of NRAS mutations and their relationship with clinical, pathologic, and molecular features remains uncertain. We developed and validated a Pyroseqencing assay to detect NRAS mutations at codons 12, 13, and 61. Using a collection of 225 colorectal cancers from 2 prospective cohort studies, we examined the relationship between NRAS mutations, clinical outcome, and other molecular features, including mutation of KRAS, BRAF, and PIK3CA, microsatellite instability, and the CpG island methylator phenotype. Finally, we examined whether NRAS mutation was associated with patient survival or prognosis. NRAS mutations were detected in 5 (2.2%) of the 225 colorectal cancers and tended to occur in left-sided cancers arising in women, but did not seem to be associated with any of the molecular features that were examined.
Source: Diagnostic Molecular Pathology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer, Genetic and genomic analysis of Ras signaling in colorectal cancer progression, In vivo systems biology of inflammatory response in the intestinal epithelium, Dietary and Hormonal Determinants of Cancer in Women, Molecular Epidemiology of Colorectal Cancer, Prospective Studies of Diet and Cancer in Men and Women
OpenAlex ID: W1973106178
